Order Article Reprints

Jannier S, Kemmel V, Sebastia Sancho C, Chammas A, Sabo A-N, Pencreach E, Farace F, Chenard MP, Lhermitte B, Geoerger B, et al. SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers. Cancers. 2020; 12(10):3051. https://doi.org/10.3390/cancers12103051

Jannier, Sarah, Véronique Kemmel, Consuelo Sebastia Sancho, Agathe Chammas, Amelia-Naomie Sabo, Erwan Pencreach, Françoise Farace, Marie Pierre Chenard, Benoit Lhermitte, Birgit Geoerger, and et al. 2020. "SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers" Cancers 12, no. 10: 3051. https://doi.org/10.3390/cancers12103051

Jannier, S., Kemmel, V., Sebastia Sancho, C., Chammas, A., Sabo, A.-N., Pencreach, E., Farace, F., Chenard, M. P., Lhermitte, B., Geoerger, B., Aerts, I., Frappaz, D., Leblond, P., André, N., Ducassou, S., Corradini, N., Bertozzi, A. I., Guérin, E., Vincent, F., ... Entz-Werle, N. (2020). SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers. Cancers, 12(10), 3051. https://doi.org/10.3390/cancers12103051